Two additional prognostic indicators in FLT3-ITD-positive AML cases established in the last few years are the mutational burden in each patient defined as the ratio between mutant and wild-type FLT3-ITD alleles (allelic ratio, AR) [12, 17, 18] and the co-occurrence of FLT3-ITD with a cytogenetically cryptic translocation of chromosomes 5 and 11 or t(5;11)(q35;p15) [19]. The gene discussed is FLT3; the disease is acute myeloid leukemia.